StartUps
– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin...
Hi, what are you looking for?
– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin...
– Why ? Because : “Israel took third place in the “Innovation” category in the latest Global Competitiveness Ranking published by the World Economic Forum....
– – Internal incisions are tricky. Unlike exterior cuts, internal ones are constantly surrounded by fluids, a fact that renders many adhesives useless. When...
– Yuri Milner / Getty – Last week, GenapSys a provider of Next Generation Sequencing (NGS) systems, announced it had raised US$37 million to...
– – To screen for colorectal cancer, both men and women over 50 are advised to undergo a colonoscopy every 10 years. Unfortunately, because...
– Two lung cancer patients in Japan were successfully treated with the company’s IceSense3 cryotherapy system. – – IceCure Ltd. (TASE: ICCM) has announced that, as...
– Photo Source / Wikimedia Commons – Afraid of needles? You’re not alone. According to to HealthLine, approximately one in five people suffer from...
– Hezi Himmelfarb, CEO of IceCure Medical explains that the disease can now be eradicated through freezing tumors into a ball of ice. ....
– Can-Fite BioPharma Ltd. (TASE: CFBI), (OTCQB: CANFY) and its subsidiary, OphthaliX Inc. (OTCQB: OPLI), jointly announced today that the U.S. Patent and Trademark Office...
– The company has developed a minimally invasive aesthetic surgical product for falling breasts. – Wonder Bra – Orbix Medical Ltd., which has developed...